Drugs / QL2107
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06173011 | Dec 2023 → Jul 2024 | neoplasm | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07453394 | Apr 2026 → Apr 2027 expected | endometrial cancer, gastric cancer, non-small cell lung carcinoma, ovarian cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07256782 | Oct 2025 → Oct 2026 expected | neoplastic disease or syndrome | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06949761 | Jun 2025 → Sep 2026 overdue | neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06911827 | May 2025 → Dec 2027 expected | neoplasm | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07151872 | Sep 2025 → Oct 2026 expected | bile duct carcinoma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06942767 | Jun 2025 → Dec 2026 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07802821 | Oct 2026 → Mar 2029 expected | small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07162883 | Sep 2025 → Dec 2026 expected | non-small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06754644 | Jan 2025 → Dec 2026 expected | non-small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL2107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06942767 ↗ |
| Route | Intravenous | “intravenous infusion” NCT06173011 ↗ |